Evidence map›Paper›PMID 32170663›Full record

ArticleDrugs - real world outcomes2020

The Healthcare Professionals' Perspective on Impact and Actions Taken Following Severe Infusion Reaction Events in Oncology Centers in Europe.

George Kafatos, Sabada Dube, Peter Burdon, Kimberly Lowe, Marjorie Leclerc, Alain Flinois, Gaston Demonty

Open access · goldAbstract read
In one paragraph

Article in Drugs - real world outcomes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

George KafatosCenter for Observational Research, Amgen Ltd, Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, England, UK. gkafatos@amgen.com.ORCID http://orcid.org/0000-0001-7871-9216
Sabada DubeCenter for Observational Research, Amgen Ltd, Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, England, UK.ORCID http://orcid.org/0000-0001-8631-8244
Peter BurdonEU Medical Affairs, Amgen (Europe) GmbH, Rotkreuz, Switzerland.ORCID http://orcid.org/0000-0002-7528-025X
Kimberly LoweCenter for Observational Research, Amgen Inc, Thousand Oaks, CA, USA.ORCID http://orcid.org/0000-0001-6827-1796
Marjorie LeclercRWE/Epi Studies, Kantar Health, Paris, France.ORCID http://orcid.org/0000-0002-7489-8058
Alain FlinoisRWE/Epi Studies, Kantar Health, Paris, France.ORCID http://orcid.org/0000-0001-9842-1046
Gaston DemontyMedical Development, Amgen, Avenue Ariane/Arianelaan 5, 1200, Brussels, Belgium.ORCID http://orcid.org/0000-0003-0626-9222
Amgen (United Kingdom) · GBAmgen (Belgium) · BEAmgen (Switzerland) · CHAmgen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe study aim was to describe the management strategies used for severe infusion-related reactions (SIRs) and understand the impact of such events in oncology day hospitals in France, Germany, Spain, and the UK.

methodsThe study was based on qualitative telephone interviews and quantitative self-completion questionnaires and asked healthcare professionals about the impact of SIRs and consequent actions taken.

resultsThe procedures to prevent and manage SIRs were similar across countries and settings. In all countries, they were part of a larger risk-assessment and adverse events-prevention process. Preventive measures included patient history, risk assessment, pre-medication, and close monitoring of high-risk patients. The management procedures comprised stopping the infusion, triggering of the emergency chain, administering corticosteroids ± antihistamines, and hospitalization if necessary. The recalled SIRs had important consequences to affected patients, healthcare providers, and hospital organizational plans. All affected patients needed to be monitored closely for a prolonged time, thus blocking hospital beds. 44% of patients needed to be hospitalized, 17% needed resuscitation, and one patient died of cardiac arrest immediately after the start of the infusion. Importantly, 82% of patients were not re-challenged with the presumedly SIR-causing regimen or re-challenged in a later line.

conclusionSIRs are unpredictable in nature, may have an extremely rapid onset, and are potentially fatal. Such events have a profound impact on the affected and surrounding patients, the care team and the organizational plan of the day-hospitals. Specific tools to reliably identify high-risk patients and predict the occurrence of events are needed.

Identifiers

PMID32170663
PMCPMC7221054
OpenAlexW3012062291

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.